Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.03 USD | -0.14% | +0.05% | -12.46% |
05-20 | Exelixis Settles Cabometyx Patent Litigation with Cipla | MT |
05-14 | Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.46% | 6.13B | |
+8.89% | 115B | |
+13.17% | 107B | |
-13.68% | 22.31B | |
-4.08% | 21.6B | |
-5.69% | 18.23B | |
-38.57% | 17.62B | |
+7.41% | 14.26B | |
+34.42% | 12.37B | |
-27.51% | 8.28B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Earnings Flash (EXEL) EXELIXIS Reports Q1 Revenue $425.2M, vs. Street Est of $460.5M